

Literatura ACTA MEDICINAE 8–9/2024 Pneumoonkologie | Pneumologie

- 2 **Imunoonkoterapie a cílená léčba časných stadií nemalobuněčného karcinomu plic**
MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha
- 2 **Imunoterapie v léčbě pokročilého nemalobuněčného karcinomu plic**
MUDr. Ondřej Bílek Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 3 **Farmakologicky ovlivnitelné méně časté mutace nemalobuněčného karcinomu plic**
MUDr. Jaromír Roubec, Ph.D. Plicní oddělení, Nemocnice Agel Ostrava-Vítkovice, a. s., a Komplexní onkologické centrum Nový Jičín
- 4 **Lorlatinib vs. crizotinib v léčbě pokročilého ALK pozitivního nemalobuněčného karcinomu plic: pětiletá data ze studie CROWN**
doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 4 **Malobuněčný karcinom – současné možnosti léčby a výhledy do budoucna**
MUDr. Simona Paulíková, Ph.D. | MUDr. Adam Paulík Klinika onkologie a radioterapie, LF UK v Hradci Králové a FN Hradec Králové
MUDr. Michal Hrnčiarik | MUDr. Michal Jiroušek Plicní klinika, FN Hradec Králové
doc. MUDr. Milan Vošmik, Ph.D. Klinika onkologie a radioterapie, LF UK v Hradci Králové a FN Hradec Králové
- 5 **Cílená léčba pacientů s nemalobuněčným plicním karcinomem – současné možnosti a výhledy**
MUDr. Markéta Černovská Pneumologická klinika, 1. LF UK a Thomayerova nemocnice, Praha
- 5 **Idiopatická plicní fibróza v roce 2024**
doc. MUDr. Martina Šterclová, Ph.D. Pneumologická klinika, 2. LF UK a FN v Motole, Praha
- 5 **Funkční vyšetření dýchacího systému – současné trendy**
MUDr. Jana Kociánová Plicní ambulance Alveolus, s. r. o., Ostrava-Poruba
- 5 **Současné možnosti léčby chronické obstrukční plicní nemoci**
MUDr. Věra Děrgelová Plicní oddělení, Nemocnice AGEL Ostrava-Vítkovice
- 5 **Očkování proti pneumokokům**
doc. MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha
- 6 **Poruchy imunitního systému – imunodeficience**
doc. MUDr. Zita Chovancová, Ph.D. Ústav klinické imunologie a alergologie, FN u sv. Anny v Brně a LF Masarykovy univerzity, Brno

Imunoonkoterapie a cílená léčba časných stadií nemalobuněčného karcinomu plic

MUDr. Leona Koubková Pneumologická klinika 2. LF UK a FN v Motole, Praha

- Girard, N. – Spicer, J. – Provencio, M., et al.: Nivolumab plus platinum-doublet chemotherapy vs chemo as neoadjuvant treatment for resectable (IB-IIIa) non-small cell lung cancer: Event-free survival results from the phase 3 CheckMate 816 trial. AACR Annual Meeting 2022. Abstrakt CT012. Prezentováno 11. 4. 2022.
- OPDIVO (nivolumab). Souhrn údajů o přípravku, 2024, dostupné z: https://ec.europa.eu/health/documents/community-registry/2023/20230424159139/anx_159139_cs.pdf, vyhledáno 4. 6. 2024.
- Wakelee, H. – Liberman, M. – Kato, T., et al.: Perioperative pembrolizumab for early-stage non-small-cell lung cancer. *N Engl J Med*, 2023, 389, s. 491–503.
- Spicer, J. D. – Gao, S. – Liberman, M., et al.: LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). *An Oncol*, 2023, 34, s. S1297–S1298.
- Cascone, T. – Awad, M. M. – Spice, J. D., et al.: LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. *An Oncol*, suppl. 2, 2023, s. S1295, doi: 10.1016/j.jannonc.2023.10.050.
- Heymach, J. V. – Harpole, D. – Mitsudomi, T., et al.: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. AACR Annual meeting 2023, abstrakt CT005.
- Heymach, J. V. – Harpole, D. – Mitsudomi, T., et al.: Perioperative durvalumab for resectable non-small-cell lung cancer. *N Engl J Med*, 2023, 389, s. 1672–1684.
- Wakelee, H. A. – Altorki, N. K. – Zhou, C., et al.: IMPower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIa non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2021, 39, suppl 15, abstrakt 8500, doi: 10.1200/JCO.2021.39.15_suppl.8500.
- Paz-Ares, L. – O'Brien, M. E. R. – Mauer, M., et al.: VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study. 17. 3. 2022, doi: <https://doi.org/10.1016/j.jannonc.2022.02.224>.
- O'Brien, M. – Paz-Ares, L. – Marreaud, S., et al.: Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIa non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. *Lancet Oncol*, 2022, 23, s. 1274–1286.
- Herbst, R. S. – Tsuboi, M. – John, T., et al.: Osimertinib as adjuvant therapy in patients (pts) with stage IB-IIIa EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. *J Clin Oncol*, 38, suppl. 18, LBAS–LBAS.
- Tsuboi, M. – Herbst, R. A., et al.: Overall survival with osimertinib in resected EGFR-mutated NSCLC. *N Engl J Med*, 2023, 389, s. 137–147.
- Solomon, B. J., et al.: LBA2 ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). *An Oncol*, 2023, suppl. 2, S1295–S1296, doi.org/10.1016/j.jannonc.2023.10.051.
- Yi-Ling, W. – Dziadziuszko, R. – Seok Ahn, J., et al.: Alectinib in resected ALK-positive non-small-cell lung cancer. *N Engl J Med*, 2024, 390, s. 1265–1276.
- Felip et al.: IMPower010: Overall survival interim analysis of a phase III study of atezolizumab vs best supportive care in resected NSCLC. Prezentováno na WCLC 2022.

Imunoterapie v léčbě pokročilého nemalobuněčného karcinomu plic

MUDr. Ondřej Bílek Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

- Bílek, O.: Možnosti léčby karcinomu plic durvalumabem v roce 2021. *Remedia*, 2021, 32. Dostupné z: https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf, vyhledáno 30. 1. 2021.
- Hodi, F. S. – Ballinger, M. – Lyons, B., et al.: Immune-Modified Response Evaluation Criteria In Solid Tumors (ImRECIST): Refining guidelines to assess the clinical benefit of cancer immunotherapy. *J Clin Oncol*, 2018, 36, s. 850–858.
- Haanen, J. B. – Carbone, F. – Robert, C., et al.: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2018, 29, suppl. 4, s. iv264–iv266.
- Reck, M. – Rodríguez-Abreu, D. – Robinson, A. G., et al.: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *N Engl J Med*, 2016, 375, s. 1823–1833.
- Reck, M. – Rodríguez-Abreu, D. – Robinson, A. G., et al.: OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs platinum-based chemotherapy for advanced non-small-cell lung cancer. *J Thoracic Oncol*, 2019, 14, s. S243. Dostupné z: <https://www.jto.org/action/showPdf?pii=S1556-0864%2819%2931166-9>, vyhledáno 7. 5. 2024.
- SPC KEYTRUDA. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf, vyhledáno 7. 5. 2024.
- Mariamidze, E. – Mezquita, L.: ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update. *ESMO Open*, 2021, 6, 100022.
- Gandhi, L. – Rodríguez-Abreu, D. – Gadgeel, S., et al.: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med*, 2018, 378, s. 2078–2092.
- Gadgeel, S. – Rodríguez-Abreu, D. – Speranza, G., et al.: Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. *J Clin Oncol*, 2020, 38, s. 1505–1517.
- Garassino, M. C. – Gadgeel, S. – Speranza, G., et al.: Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. *J Clin Oncol*, 2023, 41, s. 1992–1998.
- Paz-Ares, L. – Luft, A. – Vicente, D., et al.: Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med*, 2018, 379, s. 2040–2051.
- Paz-Ares, L. – Vicente, D. – Tafreshi, A., et al.: A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407. *J Thorac Oncol*, 2020, 15, s. 1657–1669.
- Novello, S. – Kowalski, D. M. – Luft, A., et al.: Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. *J Clin Oncol*, 2023, 41, s. 1999–2006.
- Borghaei, H. – Paz-Ares, L. – Horn, L., et al.: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *N Engl J Med*, 2015, 373, s. 1627–1639.
- Brahmer, J. – Reckamp, K. L. – Baas, P., et al.: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *N Engl J Med*, 2015, 373, s. 123–135.
- Borghaei, H. – Brahmer, J. R. – Horn, L., et al.: Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses. *JCO*, 2016, 34, suppl. 15, s. 9025–9025.
- SPC OPDIVO. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf, vyhledáno 7. 5. 2024.
- Borghaei, H. – Gettinger, S. – Vokes, E. E., et al.: Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung cancer. *J Clin Oncol*, 2021, 39, s. 723–733.
- Reck, M. – Ciuleanu, T. E. – Dols, M. C., et al.: Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. *JCO*, 2020, 38, suppl. 15, s. 9501–9501.
- Paz-Ares, L. – Ciuleanu, T. E. – Cobo, M., et al.: First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. *Lancet Oncol*, 2021, 22, s. 198–211.
- Carbone, D. P. – Ciuleanu, T. E. – Schenker, M., et al.: First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS). *JCO*, 2023, 41, suppl. 17, LBA9023–LBA9023, doi:10.1200/JCO.2023.41.17_suppl.LBA9023.
- Opdivo | European Medicines Agency. Dostupné z: <https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo>, vyhledáno 13. 5. 2024.
- Sezer, A. – Kilickap, S. – Gümüş, M., et al.: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. *Lancet*, 2021, 397, s. 592–604.
- Özgüröglu, M. – Kilickap, S. – Sezer, A., et al.: First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*, 2023, 24, s. 989–1001.
- Libtayo | European Medicines Agency. Dostupné z: <https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo>, vyhledáno 13. 5. 2024.
- Baramidze, A. – Gogishvili, M. – Melkadze, T., et al.: 122MO Cemiplimab (cemi) + platinum doublet chemotherapy (chemo) + ipilimumab (ipi) for first-line treatment of advanced non-small cell lung cancer (NSCLC): EMPOWER-Lung 3 part I. *Immuno-Oncology and Technology*, 2022, 16, 100234.
- Makharadze, T. – Gogishvili, M. – Melkadze, T., et al.: Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-Lung 3 Part 2 trial. *J Thorac Oncol*, 2023, 18, s. 755–768.
- European Commission Approves Cemiplimab Plus Chemotherapy for First-line PD-L1+ NSCLC. OnLive. Publikováno 29. 3. 2023. Dostupné z: <https://www.onclive.com/view/european-commission-approves-cemiplimab-plus-chemotherapy-for-first-line-pd-l1-nsclc>, vyhledáno 13. 5. 2024.
- SPC Tecentriq. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf, vyhledáno 13. 5. 2024.
- Rittmeyer, A. – Barlesi, F. – Waterkamp, D., et al.: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet*, 2017, 389, s. 255–265.
- von Pawel, J. – Bordoni, R. – Satouchi, M., et al.: Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. *Eur J Cancer*, 2019, 107, s. 124–132.
- Mazieres, J. – Rittmeyer, A. – Gadgeel, S., et al.: Atezolizumab versus docetaxel in pretreated patients with NSCLC: Final results from the randomised phase 2 POPLAR and phase 3 OAK clinical trials. *J Thor Oncol*, 2021, 16, s. 140–150.
- Herbst, R. S. – Giaccone, G. – de Marinis, F., et al.: Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. *N Engl J Med*, 2020, 383, s. 1328–1339.
- Jassem, J. – Herbst, R. S. – de Marinis, F., et al.: IMPower10: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC). *JCO*, 2020, 38, suppl. 15, s. e21623–e21623.
- Socinski, M. A. – Jotte, R. M. – Cappuzzo, F., et al.: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. *N Engl J Med*, 2018, 378, s. 2288–2301.
- Socinski, M. A. – Mok, T. S. – Nishio, M., et al.: Abstract CT216: IMPower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups. *Cancer Res*, 2020, 80, suppl. 16, s. CT216–CT216.
- Reck, M. – Mok, T. S. K. – Nishio, M., et al.: Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMPow-er150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. *Lancet Respir Med*, 2019, 7, s. 387–401.
- Johnson, M. L. – Cho, B. C. – Luft, A., et al.: Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. *J Clin Oncol*, 3, 11. 2022, doi:10.1200/JCO.22.00975.
- EMA. Tremelimumab AstraZeneca. European Medicines Agency. Dostupné z: <https://www.ema.europa.eu/en/medicines/human/EPAR/tremelimumab-astrazeneca>, vyhledáno 13. 5. 2024.
- EU Approves Durvalumab/Tremelimumab Combo for Advanced Lung, Liver Cancers. OnLive. Publikováno 22. 2. 2023. Dostupné z: <https://www.onclive.com/view/eu-approves-durvalumab-tremelimumab-combo-for-advanced-lung-liver-cancers>, vyhledáno 13. 5. 2024.
- Reck, M. – Rodríguez-Abreu, D. – Robinson, A. G., et al.: Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \geq 50. *J Clin Oncol*, 2021, 39, s. 2339–2349.
- Rodríguez-Abreu, D. – Powell, S. F. – Hochmair, M. J., et al.: Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. *Ann Oncol*, 2021, 32, s. 881–895, doi: 10.1016/j.jannonc.2021.04.008.
- Gray, et al.: Prezentováno na WCLC 2020. Abstrakt FP13.02.

Farmakologicky ovlivnitelné méně časté mutace nemalobuněčného karcinomu plic

MUDr. Jaromír Roubec, Ph.D. Plicní oddělení, Nemocnice Agel Ostrava-Vítkovice, a. s., a Komplexní onkologické centrum Nový Jičín

- Cox, A. D. – Fesik, S. W. – Kimmelman, A. C., et al.: Drugging the undruggable RAS: Mission possible? *Nat Rev Drug Discov*, 2014, 13, s. 828–851.
- Biernacka A. – Tsongalis, P. D. – Peterson, J. D., et al.: The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. *Cancer Genet*, 2016, 209, s. 195–198.
- Tamiya, Y., et al.: Poster presentation at American Society of Clinical Oncology (ASCO) 2020 Virtual Meeting; 29. 5. – 2. 6. 2020. Abstrakt s. 589.
- Liu, Y. – Li, H. – Zhu, J., et al.: The prevalence and concurrent pathogenic mutations of KRAS G12C in Northeast Chinese non-small-cell lung cancer patients. *Cancer Manag Res*, 2021, 13, s. 2447–2454.
- Neumann, J. – Zeindl-Eberhart, E. – Kirchner, T., et al.: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. *Pathol Res Pract*, 2009, 205, s. 858–862.
- Jones, R. P., et al.: Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. *Br J Cancer*, 2017, 116, s. 923–929.
- Wiesweg, M., et al.: Impact of RAS mutation subtype on clinical outcome—a cross-entirety comparison of patients with advanced non-small cell lung cancer and colorectal cancer. *Oncogene*, 2019, 38, s. 2953–2966.
- Nollman, F. I., et al.: Targeting mutant KRAS in pancreatic cancer: futile or promising? *Biomedicines*, 2020, 8, s. 281.
- Canon, J. – Rex, K. – Saiki, A. Y., et al.: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature*, 2019, 575, s. 217–223.
- Nassar, A. H., et al.: Distribution of KRAS G12C somatic mutations across race, sex, and cancer type. *N Engl J Med*, 2021, 384, s. 185–187.
- Canon, J. – Rex, K. – Saiki, A. Y., et al.: The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. *Nature*, 2019, 575, s. 217–223.
- Linman, B. A., et al.: Presented at: American Association for Cancer Research (AACR) Annual Meeting; 29. 3. – 3. 4. 2019; Atlanta, GA. Abstrakt #2738. Dostupné z: <https://www.aacr.org/about-the-aacr/newsroom/news-releases/aacr-to-host-2019-annual-meeting-in-atlanta-march-29-april-3/>, vyhledáno 2. 5. 2024.
- Ryan, M. B. – Corcoran, R. B., et al.: Therapeutic strategies to target RAS-mutant cancers. *Nat Rev Clin Oncol*, 2018, 15, s. 709–720.
- Simanshu, D. K. – Nissley, D. V. – McCormick, F.: RAS proteins and their regulators in human disease. *Cell*, 2017, 170, s. 17–33.
- Neel, N. F., et al.: The RalGEF-Ral effector signaling network: The road less traveled for anti-Ras drug discovery. *Genes Cancer*, 2011, 2, s. 275–287.
- Ahmadzade, T. – Tao, S. – Reid, G., et al.: An update on predictive biomarkers for treatment selection in non-small cell lung cancer. *J Clin Med*, 2018, 7, s. 153.
- Cox, A. D. – Fesik, S. W., et al.: Drugging the undruggable RAS: Mission possible? *Nat Rev Drug Discov*, 2014, 13, s. 828–851.
- Ferrer, I. – Zugazagoitia, J. – Herberich, S., et al.: KRAS-mutant non-small cell lung cancer: From biology to therapy. *Lung Cancer*, 2018, 124, s. 53–64.
- SPC Rozlytrek. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf, vyhledáno 2. 5. 2024.
- Birchmeier, C. – O'Neill, K. – Riggs, M., et al.: Characterization of ROS1 cDNA from a human glioblastoma cell line. *Proc Natl Acad Sci U S A Biochemistry*, 1990, 87, s. 4799–4803.
- Rikova, K. – Guo, A. – Zeng, Q., et al.: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell*, 2007, 131, s. 1190–203.
- Gainor, J. F. – Shaw, A. T.: Novel targets in non-small cell lung cancer: ROS1 and RET fusions. *Oncologist*, 2013, 18, s. 865–875.
- Travis, W. D. – Asamura, H. – Bankier, A. A., et al.: The IASLC Lung Cancer Staging Project: Proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. *J Thorac Oncol*, 2016, 11, s. 1204–1223.
- Bergethon, K. – Shaw, A. T. – Ou, S.-H. I., et al.: ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol*, 2012, 30, s. 863–870.
- Dugay, F. – Llamas-Gutierrez, F. – Gournay, M., et al.: Clinicopathological characteristics of ROS1- and RET-rearranged NSCLC in caucasian patients: Data from a cohort of 713 non-squamous NSCLC lacking KRAS/EGFR/HER2/BRAF/PIK3CA/ALK alterations. *Oncotarget*, 2017, 8, s. 53336–53351. doi.org/10.18632/oncotarget.18408.
- Farago, A. F. – Taylor, M. S. – Doebele, R. C., et al.: Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion. *JCO Precis Oncol*, 2018, PO.18.00037, DOI: 10.1200/PO.18.00037.
- Marchetti, A. – Barberis, M. – Di Lorito, A., et al.: ROS1 gene fusion in advanced lung cancer in women: a systematic analysis, review of the literature, and diagnostic algorithm. *JCO Precis Oncol*, 2017, s. 1–9.
- Wilson, T. R., et al.: 5576 – Genomic characteristics and predicted ancestry of NTRK1/2/3 and ROS1 fusion-positive tumors from >165,000 pan-solid tumors. ESMO 2019. Dostupné z: <https://oncologypro.esmo.org/meeting-resources/esmo-congress-2019/Genomic-characteristics-and-predicted-ancestry-of-NTRK1-2-3-and-ROS1-fusion-positive-tumors-from-165-000-pan-solid-tumors>, vyhledáno 3. 5. 2024.
- Büchler, T., et al.: Praktický návod pro testování a cílenou léčbu dospělých pacientů se solidními nádory s genovou fúzí NTRK v běžné klinické praxi. *Klin Onkol*, 2020, 33, s. 414–419.
- Brock, T. G.: Receptors and tyrosine kinases. Dostupné z: <http://www.caymanchem.com/app/template/Article/vm/article/2187>, vyhledáno 2. 5. 2024.
- Vaishnavi, A. – Le, A. T. – Doebele, R. C.: TRKING down an old oncogene in a new era of targeted therapy. *Cancer Discov*, 2015, 5(1):25–34.
- Lin, J. J. – Shaw, A. T.: Recent advances in targeting ROS1 in lung cancer. *J Thorac Oncol*, 2017, 12, s. 1611–1625.
- Bergethon, K. – Shaw, A. T. – Ou, S.-H. I., et al.: ROS1 rearrangements define a unique molecular class of lung cancers. *JCO*, 2012, 30, s. 863–870.
- Takeuchi, K. – Soda, M. – Togashi, Y., et al.: RET, ROS1 and ALK fusions in lung cancer. *Nat Med*, 2012, 18, s. 378–381.
- Patil, T. – Smith, D. E. – Bunn, P. A., et al.: The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. *J Thorac Oncol*, 2018, 13, s. 1717–1726.
- Planchard, D. – Popat, S. – Kerr, K., et al.: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2018, 29, suppl. 4, s. iv192–iv237.
- Lindeman, N. I. – Cagle, P. T. – Aisner, D. L., et al.: Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *J Mol Diagn*, 2018, 20, s. 129–159.
- Cocco, E. – Scaltriti, M. – Drilon, A.: NTRK fusion-positive cancers and TRK inhibitor therapy. *Nat Rev Clin Oncol*, 2018, 15, s. 731–747.
- Marchiò, C. – Scaltriti, M. – Ladanyi, M., et al.: ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. *Ann Oncol*, 2019, 30, s. 1417–1427.
- Vaishnavi, A. – Le, A. T. – Doebele, R. C.: TRKING down an old oncogene in a new era of targeted therapy. *Cancer Discov*, 2015, 5, s. 25–34.
- Lin, J. J. – Shaw, A. T.: Recent advances in targeting ROS1 in lung cancer. *J Thorac Oncol*, 2017, 12, s. 1611–1625.
- Deeken, J. F. – Löscher, W.: The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. *Clin Cancer Res*, 2007, 13, s. 1663–1674.
- Lorio, A. L., et al.: Blood-brain barrier and breast cancer resistance protein: A limit to the therapy of CNS tumors and neurodegenerative diseases. *Anti-Cancer Agents in Medicinal Chemistry*, 2016, 16, 810–815.
- Misra, A. – Ganesh, S., et al.: Drug delivery to the central nervous system: a review. *J Pharm Pharmaceut Sci*, 2003, 6, s. 252–273.
- Levin, V. A., et al.: CNS Anticancer Drug Discovery and Development Conference White Paper. *Neuro-Oncol*, 2015, 17, suppl. 6, s. vi1–vi26.
- Fischer, H. – Ullah, M. – de la Cruz, C. C., et al.: Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. *Neuro-Oncol*, 2020, 22, s. 819–829.
- Jena, A., et al.: Magnetic resonance (MR) patterns of brain metastasis in lung cancer patients: correlation of imaging findings with symptom. *J Thorac Oncol*, 2008, 3, s. 140–144.
- Krebs, M. G., et al.: 1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis. ESMO Virtual Congress 2020. Dostupné z: <https://doi.org/10.1016/j.jannonc.2020.08.1601>, vyhledáno 2. 5. 2024.
- Lin, C. – Wang, S. – Xie, W., et al.: The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis. *Cancer Biol Ther*, 2015, 16, s. 1019–1028.
- Gautschi, O. – Milia, J. – Filleron, T., et al.: Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry. *J Clin Oncol*, 2017, 35, s. 1403–1410.
- Drilon, A. – Lin, J. J. – Filleron, T., et al.: Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. *J Thorac Oncol*, 2018, 13, s. 1595–1601.
- Digumarthy, S. R., et al.: Imaging features and patterns of metastasis in non-small cell lung cancer with RET rearrangements. *Cancers*, 2020, 12, s. 693.
- Cancer Stat Fact: Lung and Bronchus Cancer. SEER. Dostupné z: <https://seer.cancer.gov/statfacts/html/lungb.html>, vyhledáno 2. 5. 2024.
- Subbiah, V. – Gaiaron, F. J. – Rahal, R., et al.: Precision targeted therapy with BLU-667 for RET-driven cancers. *Cancer Discov*, 2018, 8, s. 836–849.
- Evans, E. K., et al.: Poster P2.03-44 presented at the International Association for the Study of Lung Cancer, World Conference on Lung Cancer (IASLC); 7–10. 9. 2019, Barcelona, Španělsko.
- Doi, T., et al.: Safety, pharmacokinetics, and antitumor activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. *Lancet Oncol*, 2017, 18, s. 1512–1522.
- Li, B. T. – Smit, E. F. – Goto, Y., et al.: Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. *N Engl J Med*, 2022, 386, s. 241–251.
- Goto, K. – Goto, Y. – Kubo, T., et al.: Trastuzumab deruxtecan in

- patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. *J Clin Oncol*, 2023, 41, s. 4852–4863.
- 81 Nakada, T. – Sugihara, K. – Jikoh, T., et al.: The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. *Chem Pharm Bull*, 2019, 67, s. 173–185.
- 82 Peruzzi, B. – Bottaro, D. P.: Targeting the c-Met signaling pathway in cancer. *Clin Cancer Res*, 2006, 12, s. 3657–3660.
- 83 Smit, E. F., et al.: ESMO 2022. Poster 985P. Dostupné z: <https://www.esmo.org/meeting-calendar/past-meetings/esmo-congress-2022>, vyhledáno 2. 5. 2024.
- 84 Paik, P. K. – Felip, E. – Veillon, R., et al.: Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. *N Engl J Med*, 2020, 383, s. 931–943.
- 85 Le, X., et al.: Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice. *Clin Cancer Res*, 2022, 28, s. 1117–1126.
- 86 Felip, E. – Garassino, M. C. – Sakai, H., et al.: P45.03 tepotinib in patients with MET exon 14 (METex14) skipping NSCLC as identified by liquid (LBx) or tissue (TBx) biopsy. WCLC 2021.
- 87 Smit, E. F., et al.: ESMO 2022. Poster 985P. Dostupné z: <https://www.esmo.org/meeting-calendar/past-meetings/esmo-congress-2022>, vyhledáno 2. 5. 2024.
- 88 Garassino, M. C., et al.: EVOKE-01: An ongoing phase III trial comparing sacituzumab govitecan to docetaxel for NSCLC progressing on or after platinum-based chemotherapy and checkpoint inhibitors. ASCO 2022, abstrakt EP08.01–073.
- 89 Morise, M., et al.: Presentation 013–4. ESMO 2022. Dostupné z: <https://www.esmo.org/meeting-calendar/past-meetings/esmo-congress-2022>, vyhledáno 2. 5. 2024.
- 90 Yang J., et al.: CSO 2021. Poster 10157. Dostupné z: <https://www.cscocn.cn/cat/13/show/564.html>, vyhledáno 2. 5. 2024.
- 91 Thomas, M., et al.: OA03.05 Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Primary analysis of the confirmatory VISION cohort C. WCLC 2022. Abstrakt OA03.05. DOI: <https://doi.org/10.1016/j.jtho.2022.07.024>.
- 92 Le, X. – Sakai, H. – Felip, E., et al.: Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: outcomes in patient subgroups from the VISION study with relevance for clinical practice. *Clin Cancer Res*, 2022, 28, s. 1117–1126.
- 93 Mazieres, J., et al.: WCLC 2020. Abstrakt 1785. Dostupné z: <https://www.ilcn.org/category/wclc-2020-archive/>, vyhledáno 2. 5. 2024.
- 94 Planchard D. – Kim, T. M. – Mazieres, J., et al.: Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. *Lancet Oncol*, 2016, 17, s. 642–650.
- 95 Planchard, D. – Smit, E. F. – Groen, H. J. M., et al.: Updated survival of patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BR113928 study. *J Clin Oncol*, 2017, 28, suppl. 5, s. 9075.
- 96 Planchard, D. – Besse, B. – Groen, H. J. M., et al.: Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. *Lancet Oncol*, 2016, 17, s. 984–993.
- 97 Planchard, D. – Smit, E. F. – Groen, H. J. M., et al.: Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, phase 2 trial. *Lancet Oncol*, 2017, 18, s. 1307–1316.
- 98 Planchard D., et al.: Updated overall survival (OS) and genomic analysis from a single-arm phase II study of dabrafenib (D) + trametinib (T) in patients (pts) with BRAF V600E mutant (Mut) metastatic non-small cell lung cancer (NSCLC). *J Clin Oncol*, 2020, 38, suppl. 15, abstrakt 9593, https://doi.org/10.1200/JCO.2020.38.15_suppl.9593.
- 99 Planchard D. – Popat, S. – Kerr, K., et al.: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 2018, 29, suppl. 4, s. iv192–iv237.
- 100 Dostupné z: <https://www.linksos.cz/lekar-a-multidisciplinari-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/>, vyhledáno 2. 5. 2024.
- 101 Dostupné z: www.sukl.cz.
- 102 Pao, W. – Hutchinson, K. E.: Chipping away at the lung cancer genome. *Nat Med*, 2012, 18, s. 349–351.
- 103 Sos, M. L. – Dietlein, F. – Peifer, M., et al.: A framework for identification of actionable cancer genome dependencies in small cell lung cancer. *Proc Natl Acad Sci U S A*, 2012, 109, s. 17034–17039.
- 104 Dy, G. K., et al.: Presented at: American Association for Cancer Research (AACR) Annual Meeting, 8–13. 4. 2022. New Orleans, LA.

Lorlatinib vs. crizotinib v léčbě pokročilého ALK pozitivního nemalobuněčného karcinomu plic: pětiletá data ze studie CROWN

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Shaw, A. T. – Bauer, T. M. – de Marinis, F., et al.: First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. *N Engl J Med*, 2020, 383, s. 2018–2029.
- 2 FDA approves lorlatinib for metastatic ALK-positive NSCLC. Dostupné z: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lorlatinib-metastatic-alk-positive-nsclc>, vyhledáno 5. 6. 2024.
- 3 Lorlrena (lorlatinib) . Dostupné z: <https://labeling.pfizer.com/ShowLabeling.aspx?id=11140>, vyhledáno 5. 6. 2024.
- 4 Lorviqua (lorlatinib). Dostupné z: https://www.ema.europa.eu/en/documents/overview/lorviqua-epar-medicine-overview_en.pdf, vyhledáno 5. 6. 2024.
- 5 Solomon, B. J. – Bauer, T. M. – Mok, T. S. K., et al.: Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. *Lancet Respir Med*, 2023, 11, s. 354–366.
- 6 Solomon, B. J. – Liu, G. – Felip, E., et al.: Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. *J Clin Oncol*, 31. 5. 2024, JCO2400581.

Malobuněčný karcinom – současné možnosti léčby a výhledy do budoucna

MUDr. Simona Paulíková, Ph.D. | MUDr. Adam Paulík Klinika onkologie a radioterapie, LF UK v Hradci Králové a FN Hradec Králové

MUDr. Michal Hrnčíarik | MUDr. Michal Jiroušek Plicní klinika, FN Hradec Králové

doc. MUDr. Milan Vošmik, Ph.D. Klinika onkologie a radioterapie, LF UK v Hradci Králové a FN Hradec Králové

- 1 Siegel, R. L. – Miller, K. D., et al.: Cancer statistics, 2022. *CA Cancer J Clin*, 2022, 72, s. 7–33.
- 2 Ragavan, M. – Patel, M. I.: The evolving landscape of sex-based differences in lung cancer: a distinct disease in women. *Eur Respir Rev*, 2022, 31, 210100.
- 3 Khuder, S. A.: Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. *Lung Cancer*, 2001, 31, s. 139–148.
- 4 Dostupné z: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf, vyhledáno 21. 5. 2024.
- 5 Lad, T. – Piantadosi, S. – Thomas, P., et al.: A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. *Chest*, 1994, 106, suppl. 6, s. 320S–323S.
- 6 Tsuchiya, R. – Suzuki, K. – Ichinose, Y., et al.: Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I–IIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). *J Thorac Cardiovasc Surg*, 2005, 129, s. 977–983.
- 7 Yang, Y. – Zhang, D. – Zhou, X., et al.: Prophylactic cranial irradiation in resected small cell lung cancer: a systematic review with meta-analysis. *J Cancer*, 2018, 9, s. 433–439.
- 8 Rusthoven, C. G. – Kavanagh, B. D.: Prophylactic cranial irradiation (PCI) versus active MRI surveillance for small cell lung cancer: the case for equipoise. *J Thorac Oncol*, 2017, 12, s. 1746–1754.
- 9 Masciaux, C., et al.: A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. *Lung Cancer*, 2000, 30, s. 23–36.
- 10 Bunn, P. A. Jr. – Lichter, A. S. – Makuch, R. W., et al.: Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer. A prospective, randomized trial. *Ann Intern Med*, 1987, 106, s. 655–662.
- 11 Warde, P. – Payne, D.: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. *J Clin Oncol*, 1992, 10, s. 890–895.
- 12 Pijls-Johannesma, M., et al.: Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. *Cancer Treat Rev*, 2007, 33, s. 461–473.
- 13 Bogart, J., et al.: High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)/RTOG 0538. *J Clin Oncol*, 2023, 41, s. 2394–2402.
- 14 Eze, C., et al.: Treatment response and prophylactic cranial irradiation are prognostic factors in a real-life limited-disease small-cell lung cancer patient cohort comprehensively staged with cranial magnetic resonance imaging. *Clin Lung Cancer*, 2017, 18, s. e243–e249.
- 15 Rodríguez de Dios, N. – Couñago, F. – Murcia-Mejía, M., et al.: Randomized phase III trial of prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer (PREMER): a GICOR-GOCEP-SEOR study. *J Clin Oncol*, 2021, 39, s. 3118–3127.
- 16 Ready, N. E. – Ott, P. A. – Hellmann, M. D., et al.: Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. *J Thorac Oncol*, 2020, 15, s. 426–435.
- 17 Chung, H. Ch. – Piha-Paul, S. A. – Lopez-Martin, J., et al.: Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. *J Thorac Oncol*, 2020, 15, s. 618–627.
- 18 Kazarian, M. – Laird-Offringa, L. A.: Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. *Mol Cancer*, 2011, 10, s. 33.
- 19 Spigel, D. R. – Vicente, D. – Ciuleanu, T. E., et al.: Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331. *Ann Oncol*, 2021, 32, s. 631–641.
- 20 Schlick, B. – Shields, M. D. – Marin-Acevedo, J. A., et al.: Immune checkpoint inhibitors and chemoradiation for limited-stage small cell lung cancer. *Curr Treat Options Oncol*, 2022, 23, s. 1104–1120.
- 21 Calabrese, Ch. R. – Almassy, R. – Barton, S., et al.: Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. *J Natl Cancer Inst*, 2004, 96, s. 56–67.
- 22 Lochmann, T. L. – Floros, K. V. – Naseri, M., et al.: Venetoclax is effective in small-cell lung cancers with high BCL-2 expression. *Clin Cancer Res*, 2018, 24, s. 360–369.
- 23 Owonikoko, T. K. – Niu, H. – Nackaerts, K., et al.: Randomized phase II study of paclitaxel plus alectinib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses. *J Thorac Oncol*, 2020, 15, s. 274–287.
- 24 Megyesi, Z., et al.: Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. *CA Cancer J Clin*, 2023, 73, s. 620–652.
- 25 Meijer, J.-J. – Leonetti, A. – Airò, G., et al.: Small cell lung cancer: Novel treatments beyond immunotherapy. *Semin Cancer Biol*, 2022, 86, s. 376–385.
- 26 UCSD Internal Medicine Residency. Dostupné z: <https://twitter.com/ucsdim/status/1279163574020005893>, vyhledáno 21. 5. 2024.

Cílená léčba pacientů s nemalobuněčným plicním karcinomem – současné možnosti a výhledy

MUDr. Markéta Černovská Pneumologická klinika, 1. LF UK a Thomayerova nemocnice, Praha

- 1 Araki, T. – Kanta, S.: Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance. *JPN Clin Oncol*, 2023, 53, s. 547–561.
- 2 Yuan, X. – Wang, Y., et al.: A retrospective study of ensartinib-treated ALK-positive locally advanced or metastatic NSCLC patients in China. *Lung Cancer*, 2023, 12, LMT61.
- 3 Chung, E. K. – Yong, S. H., et al.: New targeted therapy for non-small cell lung cancer. *Tuberc Respir Dis*, 2023, 86, s. 1–13.
- 4 Schalm, S. S. – Dineen, T. – Lim, S. M., et al.: 384P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC. *Ann Oncol*, 2020, 31, s. S1391.
- 5 Shaw, A. T. – Felip, E. – Bauer, T. M., et al.: Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. *Lancet Oncol*, 2017, 18, s. 1590–1599.
- 6 Lee, C. K. – Wu, Y.-L. – Ding, P. N., et al.: Impact of specific epidermal growth factor receptor (EGFR) mutation and clinical characteristics on outcomes after treatment with EGFR tyrosinekinase inhibitors versus chemotherapy in EGFR-mutant lung cancer. *J Clin Oncol*, 2015, 33, s. 1958–1965.
- 7 Darren, A. – Ashton, S. E. – Ghiorghiu, S., et al.: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. *Cancer Discovery*, 2014, 4, s. 1046–1061.
- 8 SPC Rybrevant, Rybrevant, INN-amivantamab (europa.eu).
- 9 Xie, Y. – Lu, Q. – Wang, J. Q., et al.: Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer. *Drugs Today*, 2022, 58, s. 389–398.
- 10 Skříčková, J. – Kolek, V.: *Základy moderní pneumoonkologie*. Praha, Maxdorf, 2018.
- 11 Slavin, R. G. – Ferioli, C. – Tannenbaum, S. J., et al.: Asthma symptom reemergence afteromalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. *J Allergy Clin Immunol*, 2009, 123, s. 107–113.

Idiopatická plicní fibróza v roce 2024

doc. MUDr. Martina Šterclová, Ph.D. Pneumologická klinika, 2. LF UK a FN v Motole, Praha

- 1 Liebow, A. A. – Carrington, C. B.: The interstitial pneumonias. In: Simon, M. – Potchen, E. J. – LeMay, M. (eds.): *Frontiers of pulmonary radiology*. New York, Grune and Stratton, 1969, s. 102–141.
- 2 Hamman, L. – Rich, A. R.: Fulminating diffuse interstitial fibrosis of the lungs. *Trans Am Clin Climatol Assoc*, 1935, 51, s. 154–163.
- 3 American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. *Am J Respir Crit Care Med*, 2002, 165, s. 277–304.
- 4 Raghu, G. – Remy-Jardin, M. – Richeldi, L., et al.: Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med*, 2022, 205, s. e18–e47.
- 5 Sekce pro intersticiální plicní procesy | Česká pneumologie – plicní lékařství (plicnilekarstvi.cz).
- 6 Cao, U. M. N. – Zhang, Y. – Chen, J., et al.: Microfluidic Organ-on-A-chip: a guide to biomaterial choice and fabrication. *Int J Mol Sci*, 2023, 24, s. 3232.
- 7 Kolanko, E. – Cargnoni, A. – Papat, A., et al.: The evolution of in vitro models of lung fibrosis: promising prospects for drug discovery. *Eur Respir Rev*, 2024, 33, 230127.
- 8 Wu, Z. – Spencer, L. G. – Banya, W., et al.: Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial. *Lancet Respir Med*, 2024, 12, s. 273–280.
- 9 Maher, T. M. – Avram, C. – Bortey, E., et al.: Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis. *NEJM Evid*, 2023, 2, EVIDo2300083.
- 10 Humbert, M. – Kovacs, G. – Hoepfer, M. M., et al.: ESC/ERS Scientific Document Group: 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J*, 2023, 61, 2200879.
- 11 Shlobin, O. A. – Shen, E. – Wort, S. J., et al.: Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative–Group 3 Pulmonary Hypertension. *Pulm Circ*, 2024, 14, e12310.
- 12 Nathan, S. D. – Tehrani, B. – Zhao, Q., et al.: Pulmonary vascular dysfunction without pulmonary hypertension: A distinct phenotype in idiopathic pulmonary fibrosis. *Pulm Circ*, 2024, 14, e12311.
- 13 Gayá García-Manso, I. – Arenas Jiménez, J. – Hernández Blasco, L., et al.: Radiological usual interstitial pneumonia pattern is associated with two-year mortality in patients with idiopathic pulmonary fibrosis. *Heliyon*, 2024, 10, e26623.
- 14 Tesolato, S. – Vicente-Valor, J. – Jarabo, J. R., et al.: Role of telomere length in survival of patients with idiopathic pulmonary fibrosis and other interstitial lung diseases. *Biomedicines*, 2023, 11, s. 3257.
- 15 Tomos, I. – Karakatsani, A. – Manali, E. D., et al.: Telomere length across different UIP fibrotic-interstitial lung diseases: a prospective Greek case-control study. *Pulmonology*, 2022, 28, s. 254–261.
- 16 Adams, T. N. – Batra, K. – Kypreos, M., et al.: Impact of radiographic honeycombing on transplant free survival and efficacy of immunosuppression in fibrotic hypersensitivity pneumonitis. *BMC Pulm Med*, 2023, 23, s. 224.
- 17 Selman, M. – Pardo, A. – Wells, A. U.: Usual interstitial pneumonia as a stand-alone diagnostic entity: the case for a paradigm shift? *Lancet Respir Med*, 2023, 11, s. 188–196.
- 18 Zheng, B. – Marinescu, D. C. – Hague, C. J., et al.: Lung imaging patterns in connective tissue disease-associated interstitial lung disease impact prognosis and immunosuppression response. *Rheumatology*, 2024, DOI:10.1093/rheumatology/keae076.
- 19 Zhang, D. – Adegunsoye, A. – Oldham, J. M., et al.: Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. *Eur Respir J*, 2023, 62, 2300441.
- 20 Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu, G. – Anstrom, K. J. – King, T. E. Jr., et al.: Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. *N Engl J Med*, 2012, 366, s. 1968–1977.

Funkční vyšetření dýchacího systému – současné trendy

MUDr. Jana Kociánová Plicní ambulance Alveolus, s. r. o., Ostrava-Poruba

- 1 Graham, B. L., et al.: An Official American Thoracic Society and European Respiratory Society Technical Statement. *AJRCC*, 2019, 200, s. e70–e88, doi/suppl/10.1164/rccm.201908-1590ST.
- 2 Stanojević, S. – Kaminsky, D. A. – Miller, M. R., et al.: ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J*, 2021, dostupné z: <https://erj.ersjournals.com/content/60/1/2101499>, vyhledáno 5. 4. 2024.
- 3 Quanjer, P. H., et al.: Initiative ERSGLF. Multi-ethnic reference values for spirometry for the 3-95yr age range: the global lung function 2012 equations. *Eur Respir J*, 2012, 40, s. 1324–1343.
- 4 Stanojević, S., et al.: Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry. *Eur Respir J*, 2020, 57, 2000289.
- 5 King, G. G., et al.: Technical standards for oscillometry. *Eur Respir J*, 2020, 55, dostupné z: <https://erj.ersjournals.com/content/55/2/1900753>
- 6 Radtke, T., et al.: ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases. *Eur Respir Rev*, 2019, 28, 180101.
- 7 Milani, R. V., et al.: Cardiopulmonary exercise testing. How do we differentiate the cause of dyspnea? *Circulation*, 2004, 110, s. e27–e31.
- 8 Chlumský, J.: *Plicní funkce pro klinickou praxi*. Maxdorf, Praha, 2014.
- 9 Solovič, I. – Matula, B., et al.: *Funkčné vyšetřovací metody pre nelekárske zdravotnícke odbory*. Verbum, Ružomberok, 2023.
- 10 Koucký, V.: *Doporučený postup pro provedení a interpretaci spirometrie v předškolním věku*. ČPFS, 2023, www.plicnilekarstvi.cz.

Současné možnosti léčby chronické obstrukční plicní nemoci

MUDr. Věra Děrgelová Plicní oddělení, Nemocnice AGEL Ostrava-Vítkovice

- 1 Kašák, V.: *Farmakoterapie pro praxi – Chronická obstrukční plicní nemoc*. 2006, s. 15–16, s. 25–26.
- 2 Dostupné z: <https://goldcopd.org/2024-gold-report/>, vyhledáno 21. 5. 2024.
- 3 Miravittles, M. – Soler-Cataluña, J. J. – Calle, M., et al.: Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. *Pharmacological treatment of stable phase*. *Arch Bronconeumol*, 2017, 53, s. 324–335.
- 4 Kolek, V., et al.: *Doporučené postupy v pneumologii*. 2019, kap. 1.1.
- 5 Rembert, K. A., et al.: Alpha-1 antitrypsin deficiency and replacement therapy – Current developments and clinical significance 2021. Dostupné z: https://fabryclinicaltrials.com/?utm_source=google&utm_medium=paidsearch&utm_content=pxfabry&gclid=EALal-QobChMIS8Cm9q2chgMVTp2DBx2iPwOkEAAAYASAAEgkVHPD_BwE, vyhledáno 21. 5. 2024.

Očkování proti pneumokokům

doc. MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, a. s., Praha

- 1 Jakubec, P. – Kolek, V.: Komunitní pneumonie. In: *Pneumonie pro klinickou praxi*. Maxdorf Jessenius, 2018, s. 18–38.
- 2 Prymula, R.: Očkování proti pneumokokovým onemocněním. In: Chlíbek, R., et al.: *Očkování dospělých*. Mladá fronta, 2019, s. 150–161.
- 3 Kozáková, J. – Okonji, Z. – Klímová, M., et al.: Invazivní pneumokoková onemocnění v České republice v roce 2019. *Zpráva centra epidemiologie a mikrobiologie*. SZÚ, 2020, 29 (6).
- 4 Chlíbek, R.: Očkování pacientů s chronickým onemocněním. In: Chlíbek, R., et al.: *Očkování dospělých*. Mladá fronta, 2019, s. 252–358.
- 5 Prymula, R.: Očkování proti pneumokokovým onemocněním. In: Chlíbek, R., et al.: *Očkování dospělých*. Mladá fronta, 2019, s. 150–160.
- 6 SÚKL SPC Pneumovax 23. Dostupné z: https://prehledysukl.cz/prehled_liciv.html#detail-reg/0237303, vyhledáno 15. 5. 2024.
- 7 SPC Synflorix. Dostupné z: https://prehledysukl.cz/prehled_liciv.html#, vyhledáno 15. 5. 2024.

- 8 SPC Prevenar 13. Dostupné z: [https://prehledy.sukl.cz/prehled_leviv.html#/,](https://prehledy.sukl.cz/prehled_leviv.html#/) vyhledáno 15. 5. 2024.
- 9 SPC Vaxneuvance. Dostupné z: [https://prehledy.sukl.cz/prehled_leviv.html#/,](https://prehledy.sukl.cz/prehled_leviv.html#/) vyhledáno 15. 5. 2024.
- 10 SPC Prevenar 20. Dostupné z: [https://prehledy.sukl.cz/prehled_leviv.html#/,](https://prehledy.sukl.cz/prehled_leviv.html#/) vyhledáno 20. 5. 2024.
- 11 Doporučení České vakcinologické společnosti ČLS JEP pro očkování proti pneumokokovým onemocněním z 10. 4. 2024.
- 12 NZIS: Aktuální data o proočkovatelnosti české populace. Dostupné z: [https://www.nzip.cz/clanek/1704-ockovani-v-dostupnych-datech-nzis,](https://www.nzip.cz/clanek/1704-ockovani-v-dostupnych-datech-nzis) vyhledáno 21. 5. 2024.
- 13 Doporučení České vakcinologické společnosti ČLS JEP pro očkování proti pneumokokovým onemocněním z 21. 12. 2022.

Poruchy imunitního systému – imunodeficience

doc. MUDr. Zita Chovancová, Ph.D. Ústav klinické imunologie a alergologie, FN u sv. Anny v Brně a LF Masarykovy univerzity, Brno

- Bruton, O. C. – Apt, L. – Gitlin, D., et al.: Absence of serum gamma globulins. *AMA Am J Dis Child*, 1952, 84, s. 632–636.
- Mauracher, A. A. – Guje, E., et al.: Patterns of immune dysregulation in primary immunodeficiencies: a systematic review. *J Allergy Clin Immunol Pract*, 2021, 9, s. 792–802.e710.
- Tangye, S. G. – Al-Herz, W. – Bousfiha, A., et al.: Human inborn errors of immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. *J Clin Immunol*, 2020, 40, s. 24–64.
- Bousfiha, A. – Moundir, A. – Tangye, S. G., et al.: The 2022 Update of IUUIS Phenotypical Classification for Human Inborn Errors of Immunity. *J Clin Immunol*, 2022, 42, s. 1508–1520.
- O'Sullivan, M. D. – Cant, A. J.: The 10 warning signs: a time for a change? *Curr Opin Allergy Clin Immunol*, 2012, 12, s. 588–594.
- Bjelac, J. A. – Yonkof, J. R. – Fernandez, J.: Differing performance of the warning signs for immunodeficiency in the diagnosis of pediatric versus adult patients in a two-center tertiary referral population. *J Clin Immunol*, 2019, 39, s. 90–98.
- Dąbrowska, A. – Grzešk, E. – Urbańczyk, A., et al.: Extended list of warning signs in qualification to diagnosis and treatment of inborn errors of immunity in children and young adults. *J Clin Med*, 2023, 12, s. 3401.
- Takahashi, K.: Mannose-binding lectin and the balance between immune protection and complication. *Expert Rev Anti Infect Ther*, 2011, 9, s. 1179–1190.
- Tuano, K. S. – Seth, N. – Chinen, J.: Secondary immunodeficiencies: An overview. *Ann Allergy Asthma Immunol*, 2021, 127, s. 617–626.
- Grumach, A. S. – Goudouris, E. S.: Inborn errors of immunity: how to diagnose them? *J Pediatr (Rio J)*, 2021, 97, suppl. 1, s. S84–S90.
- Puck, J. M.: Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. *J Allergy Clin Immunol*, 2012, 129, s. 607–616.
- Argudo-Ramirez, A. – Martín-Nalda, A. – Marín-Soria, J. L., et al.: First Universal Newborn Screening Program for Severe Combined Immunodeficiency in Europe. Two-Years' Experience in Catalonia (Spain). *Front Immunol*, 2019, 10, s. 2406.
- Serana, F. – Chiarini, M. – Zanotti, C., et al.: Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies. *J Transl Med*, 2013, 11, s. 119.
- van der Burg, M. – Mahlaoui, N. – Gaspar, H. B., et al.: Universal newborn screening for severe combined immunodeficiency (SCID). *Front Pediatr*, 2019, 7, s. 373.
- Fischer, A.: Gene therapy for inborn errors of immunity: past, present and future. *Nat Rev Immunol*, 2023, 23, s. 397–408.
- Kuruvilla, M. – de la Morena, M. T.: Antibiotic prophylaxis in primary immune deficiency disorders. *J Allergy Clin Immunol Pract*, 2013, 1, s. 573–582.
- Miloto, C. – Soccodato, V. – Collalti, G., et al.: Vaccination in PADs. *Vaccines*, 2021, 9, s. 626.
- Eibl, M. M. – Wolf, H. M.: Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. *Immunother*, 2015, 7, s. 1273–1292.
- Lo, B. – Zhang, K. – Lu, W., et al.: Autoimmune disease. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. *Science*, 2015, 349, s. 436–440.
- Buccioli, G. – Meyts, I.: Recent advances in primary immunodeficiency: from molecular diagnosis to treatment. *F1000Res*, 2020, 9, F1000 Faculty Rev-194.